|
|
|
|
Monday, November 11, 2019
Trovagene (TROV)
Q3 2019 Results: Trovagene Continues Progressing
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Progress Made in Three Clinical Programs. Trovagene has made progress in multiple clinical programs including; initiation of Phase 2 study in acute myeloid leukemia (AML) assessing onvansertib in combination with decitabine, multiple data readouts from three clinical programs including AML, metastatic castration-resistant prostate cancer (mCRPC) and KRAS-mutated metastatic colorectal cancer (mCRC)..
- Third Quarter Results. The company reported total operating expenses of $4.3 million; $2.8 million of R&D expenses and $1.5 million in SG&A expenses. Trovagene has $9.0 million of cash and cash equivalents, as of September 30, 2019. We have updated our model incorporating reported numbers and …
Get full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.
